Skip to main content
main-content

01.05.2008 | ORIGINAL CONTRIBUTION | Ausgabe 3/2008

Basic Research in Cardiology 3/2008

Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening

Zeitschrift:
Basic Research in Cardiology > Ausgabe 3/2008
Autoren:
Gurpreet S. Bhamra, Derek J. Hausenloy, Sean M. Davidson, Richard D. Carr, Marta Paiva, Abigail M. Wynne, Mihaela M. Mocanu, Prof. Derek M. Yellon
Wichtige Hinweise
Returned for 1. Revision: 14 May 2007 1. Revision received: 18 May 2007
Returned for 2. Revision: 4 June 2007 2. Revision received: 23 October 2007

Abstract

Background

In the majority of studies, metformin has been demonstrated to cardioprotect diabetic patients, the mechanism of which is unclear. We hypothesized that metformin cardioprotects the ischemic heart through the Akt-mediated inhibition of mitochondrial permeability transition pore (mPTP) opening.

Materials and methods

Isolated perfused hearts from normoglycemic Wistar or from diabetic Goto-Kakizaki (GK) rats (N ≥ 6/group) were subjected to 35 min ischemia and 120 min of reperfusion. Metformin (50 µmol/l) was added for 15 min at reperfusion, alone or with LY294002 (15 µmol/l), a PI3K inhibitor. Infarct size and Akt phosphorylation were measured. Furthermore, the effect of metformin on mPTP opening in adult cardiomyocytes isolated from both strains was determined.

Results

Metformin reduced infarct size in both Wistar (35 ± 2.7% metformin vs. 62 ± 3.0% control: P < 0.05) and GK hearts (43 ± 4.7% metformin vs. 60 ± 3.8% control: P < 0.05). This protection was accompanied by a significant increase in Akt phosphorylation. LY294002 abolished the metformin-induced Akt phosphorylation and the infarct-limiting effect of metformin in Wistar (61 ± 6.7% metformin + LY294002 vs. 35 ± 2.7% metformin: P < 0.05) and GK rats (56 ± 5.7% metformin + LY294002 vs. 43 ± 4.7% metformin: P < 0.05). In addition, metformin significantly inhibited mPTP opening and subsequent rigor contracture in both Wistar and GK cardiomyocytes subjected to oxidative stress, in a LY-sensitive manner.

Conclusions

We report that metformin given at the time of reperfusion reduces myocardial infarct size in both the non-diabetic and diabetic heart and this protective effect is mediated through PI3K and is associated with Akt phosphorylation. Furthermore, cardioprotection appears to be executed through a PI3K-mediated inhibition of mPTP opening. These findings may explain in part the cardioprotective properties of metformin observed in clinical studies of diabetic patients.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2008

Basic Research in Cardiology 3/2008 Zur Ausgabe

INVITED EDITORIAL

Heart spotting

  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise